Thrivent Financial for Lutherans
RGNX icon

Thrivent Financial for Lutherans’s Regenxbio RGNX Stock Holding History

Thrivent Financial for Lutherans’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,205
Closed -$176K – 2649
2025
Q4 		$176K Sell
12,205
-22,798
-65% -$284K ﹤0.01% 2538
2025
Q3 		$338K Buy
+35,003
New +$310K ﹤0.01% 2200
2024
Q4 		– Sell
-35,706
Closed -$375K – 2593
2024
Q3 		$375K Sell
35,706
-1,913
-5% -$23.3K ﹤0.01% 2330
2024
Q2 		$440K Buy
37,619
+2,508
+7% +$39K ﹤0.01% 2271
2024
Q1 		$740K Sell
35,111
-953
-3% -$17K ﹤0.01% 2061
2023
Q4 		$647K Sell
36,064
-933
-3% -$16.4K ﹤0.01% 2110
2023
Q3 		$609K Buy
36,997
+822
+2% +$14.9K ﹤0.01% 2041
2023
Q2 		$723K Sell
36,175
-1,152
-3% -$22.2K ﹤0.01% 2007
2023
Q1 		$706K Sell
37,327
-1,309
-3% -$29K ﹤0.01% 1977
2022
Q4 		$876K Sell
38,636
-21,408
-36% -$484K ﹤0.01% 1812
2022
Q3 		$1.59M Buy
60,044
+22,751
+61% +$675K ﹤0.01% 1377
2022
Q2 		$921K Buy
37,293
+6,654
+22% +$166K ﹤0.01% 1758
2022
Q1 		$1.02M Buy
30,639
+10
+0% +$278 ﹤0.01% 1821
2021
Q4 		$1M Buy
30,629
+326
+1% +$11.1K ﹤0.01% 1855
2021
Q3 		$1.27M Buy
30,303
+1,807
+6% +$65K ﹤0.01% 1676
2021
Q2 		$1.11M Sell
28,496
-131
-0.5% -$4.68K ﹤0.01% 1771
2021
Q1 		$976K Buy
28,627
+3,862
+16% +$165K ﹤0.01% 1886
2020
Q4 		$1.12M Hold
24,765
– – ﹤0.01% 1673
2020
Q3 		$682K Sell
24,765
-1,731
-7% -$56.4K ﹤0.01% 1809
2020
Q2 		$976K Buy
26,496
+228
+0.9% +$8.5K ﹤0.01% 1510
2020
Q1 		$851K Buy
26,268
+1,311
+5% +$54.6K ﹤0.01% 1400
2019
Q4 		$1.02M Buy
24,957
+99
+0.4% +$3.91K ﹤0.01% 1465
2019
Q3 		$885K Buy
24,858
+858
+4% +$34.8K ﹤0.01% 1493
2019
Q2 		$1.23M Buy
24,000
+1,004
+4% +$50.1K ﹤0.01% 1268
2019
Q1 		$1.32M Buy
22,996
+1,816
+9% +$90K ﹤0.01% 1185
2018
Q4 		$888K Buy
21,180
+742
+4% +$43.5K ﹤0.01% 1231
2018
Q3 		$1.54M Buy
20,438
+2,035
+11% +$147K ﹤0.01% 1016
2018
Q2 		$1.32M Buy
+18,403
New +$879K ﹤0.01% 1086

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Thrivent Financial for Lutherans's RGNX Position: Q1 2026 in Review

Thrivent Financial for Lutherans sold out of Regenxbio (RGNX) in Q1 2026, closing a stake of 12,205 shares — an estimated $176K sold.

Thrivent Financial for Lutherans first reported a position in RGNX in Q2 2018 and held it in 28 quarters. The position peaked at $1.59M in Q3 2022. 178 funds tracked by Wall St. Rank hold RGNX as of Q1 2026.

  • Thrivent Financial for Lutherans reported no remaining Regenxbio position as of Q1 2026 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 12,205 Regenxbio shares in Q1 2026, an estimated $176K.
  • Thrivent Financial for Lutherans first reported a position in Regenxbio in Q2 2018 and held it in 28 quarters.
  • Thrivent Financial for Lutherans's Regenxbio position peaked at $1.59M in Q3 2022.
  • 178 funds tracked by Wall St. Rank held Regenxbio as of Q1 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q1 2026, filed 1 May 2026.